Atea Pharmaceuticals, Inc. — Director's Dealing 2020

Oct 30, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2020-10-29

Reporting Person: Sommadossi Jean-Pierre (Director, President, CEO, and Chairman, 10% Owner)
Reporting Person: JPM Partners LLC (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5175000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$		Common Stock (750000)		Indirect
Stock Option (Right to Buy)	$1.24	2026-12-08	Common Stock (300000)		Direct
Stock Option (Right to Buy)	$1.53	2027-12-07	Common Stock (200000)		Direct
Stock Option (Right to Buy)	$1.53	2027-12-07	Common Stock (185000)		Direct
Stock Option (Right to Buy)	$1.43	2028-12-13	Common Stock (200000)		Direct
Stock Option (Right to Buy)	$1.85	2029-12-12	Common Stock (200000)		Direct
Stock Option (Right to Buy)	$6.83	2030-08-02	Common Stock (100000)		Direct

Footnotes

F1: Each share of Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

F2: The option is fully vested and exercisable.

F3: The option vests and becomes exercisable in 36 equal monthly installments following November 30, 2017.

F4: The option is fully vested and exercisable.

F5: The option vests and becomes exercisable in 48 equal monthly installments following November 30, 2018.

F6: The option vests and becomes exercisable in 48 equal monthly installments following November 30, 2019.

F7: The option vests and becomes exercisable in 48 equal monthly installments following June 30, 2020.